step 6 semaglutide clinical trial 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo- controlled, phase 3 FLOWing with the SemagluTIDE — – Efficacy and safety of once

(accessed June 2022) 16BMI: preventing ill health and premature death in black, Asian and other minority ethnic groups

Medicare, by law, is not allowed to cover medications for weight loss, but the Biden administration last year proposed reinterpreting the statute to allow coverage for the treatment of obesity as a chronic disease

Others consume more low-calorie beverages or foods with higher water content

No evidence of tolerance development (requiring progressively higher doses to achieve the same effect) or physical dependence (withdrawal symptoms upon discontinuation) has been documented in available research, distinguishing DSIP favorably from traditional sleep medications that commonly cause both tolerance and dependence

Unexpectedly slow or absent weight loss despite consistent dosing is another red flag